VIPDOMET 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

metformin hydrochloride, Quantity: 500 mg; alogliptin benzoate, Quantity: 17 mg (Equivalent: alogliptin, Qty 12.5 mg)

Disponible desde:

Takeda Pharmaceuticals Australia Pty Ltd

Designación común internacional (DCI):

Alogliptin benzoate,Metformin hydrochloride

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: microcrystalline cellulose; mannitol; magnesium stearate; titanium dioxide; hypromellose; crospovidone; povidone; purified talc; iron oxide yellow

Vía de administración:

Oral

Unidades en paquete:

196, 20, 120, 14, 28, 112, 60, 56, 200, 98, 180, 10

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

VIPDOMET is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,VIPDOMET can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Resumen del producto:

Visual Identification: Pale yellow, oblong, biconvex, film-coated tablet with 12.5/500 debossed on one side and 322M debossed on the other side; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Registered

Fecha de autorización:

2013-10-22